Graham Pawelec

Graham Pawelec received a BA (Natural Sciences Tripos), an MA in the History and Philosophy of Science and a PhD in Transplantation Immunology from the University of Cambridge, UK, where he contributed to studies resulting in the introduction of the second-generation immunosuppressive drug Cyclosporin A. Since then, he has been an active academic researcher in immunology for over 40 years. He is currently Professor of Experimental Immunology in the Department of Immunology, University of Tübingen, Tübingen, Germany and is a member of the Cancer Solutions Program at the Health Sciences North Research Institute of Canada, Sudbury, ON, Canada. He was a Visiting Professor at Nottingham Trent University, UK and at King's College London, UK, and held an Honorary Chair at Manchester University, UK. He has published over 400 PubMed-listed papers, for an H-index of 106 (Google Scholar, January 2024). His research interests are centred on how ageing affects immune function and influences the outcome of vaccination and immunotherapy, and how immunosenescence impacts human health and longevity.